Russell Investments Group Ltd. Boosts Stake in Enliven Therapeutics, Inc. $ELVN

Key Points

• Russell Investments Group Ltd. significantly increased its stake in Enliven Therapeutics, raising its position by over 148,500% during the first quarter, owning approximately 105,542 shares worth $2,077,000.
• Insiders at Enliven Therapeutics sold a total of 115,984 shares valued at approximately $2.4 million over the last 90 days, with both the CEO and another insider reporting ownership decreases of around 1.3% after their respective sales.
• Equities research analysts remain optimistic about Enliven Therapeutics, with several raising their target prices for the stock, leading to an average target of $41.20 and a general rating of "Buy."

Russell Investments Group Ltd. raised its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 148,550.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 105,542 shares of the company's stock after acquiring an additional 105,471 shares during the period. Russell Investments Group Ltd. owned approximately 0.22% of Enliven Therapeutics worth $2,077,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Nuveen LLC purchased a new stake in Enliven Therapeutics during the first quarter valued at about $2,049,000. Invesco Ltd. boosted its position in shares of Enliven Therapeutics by 39.6% in the first quarter. Invesco Ltd. now owns 21,044 shares of the company's stock worth $414,000 after buying an additional 5,972 shares during the period. BIT Capital GmbH purchased a new stake in shares of Enliven Therapeutics in the first quarter worth about $382,000. XTX Topco Ltd purchased a new stake in shares of Enliven Therapeutics in the first quarter worth about $430,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Enliven Therapeutics by 4.5% in the first quarter. Bank of New York Mellon Corp now owns 93,567 shares of the company's stock worth $1,841,000 after buying an additional 3,992 shares during the period. Hedge funds and other institutional investors own 95.08% of the company's stock.

Insider Activity at Enliven Therapeutics

In related news, CEO Samuel Kintz sold 12,500 shares of the stock in a transaction dated Thursday, July 17th. The stock was sold at an average price of $22.52, for a total value of $281,500.00. Following the completion of the transaction, the chief executive officer owned 940,392 shares of the company's stock, valued at approximately $21,177,627.84. This represents a 1.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Joseph P. Lyssikatos sold 12,500 shares of the stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $22.29, for a total value of $278,625.00. Following the completion of the transaction, the insider directly owned 952,688 shares of the company's stock, valued at $21,235,415.52. This represents a 1.30% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 115,984 shares of company stock valued at $2,419,783. Insiders own 25.90% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. HC Wainwright upped their target price on Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a research report on Wednesday, July 2nd. Robert W. Baird upped their target price on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a research report on Monday, June 16th. The Goldman Sachs Group assumed coverage on Enliven Therapeutics in a research report on Monday, June 16th. They issued a "buy" rating and a $37.00 target price for the company. Finally, Jones Trading decreased their target price on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a research report on Friday, May 16th. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Enliven Therapeutics has an average rating of "Buy" and an average price target of $41.20.

Enliven Therapeutics Stock Performance

Shares of ELVN opened at $19.94 on Tuesday. The company has a market capitalization of $1.18 billion, a P/E ratio of -9.97 and a beta of 0.93. Enliven Therapeutics, Inc. has a one year low of $13.30 and a one year high of $30.03. The stock has a 50-day moving average price of $20.54 and a 200 day moving average price of $19.81.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.04. As a group, equities research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

Want to see what other hedge funds are holding ELVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.